[CAS NO. 948564-73-6] Fresolimumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [948564-73-6]

Catalog

HY-P99020

Brand

MCE

CAS

948564-73-6

DESCRIPTION [948564-73-6]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	Unspecified
SMILES	[Fresolimumab]

For research use only. We do not sell to patients.

Summary

Fresolimumab (GC1008) is a high-affinity fully human monoclonal antibody that neutralizes the active form of human TGFβ1 , TGFβ2 , and TGFβ3 . Fresolimumab can be used for the research of cancer and fibrotic diseases ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00356460	Genzyme, a Sanofi Company\|Sanofi	Carcinoma, Renal Cell\|Melanoma	September 2006	Phase 1
NCT03064074	Baylor College of Medicine\|Genzyme, a Sanofi Company\|Oregon Health and Science University	Osteogenesis Imperfecta	November 15, 2017	Phase 1
NCT01401062	Weill Medical College of Cornell University\|University of California, Los Angeles	Metastatic Breast Cancer	July 2011	Phase 2
NCT01284322	Boston University	Diffuse Systemic Sclerosis	January 2011	Phase 1
NCT00464321	Genzyme, a Sanofi Company\|Sanofi	Focal Segmental Glomerulosclerosis	May 2007	Phase 1
NCT01665391	Genzyme, a Sanofi Company\|Sanofi	Primary Focal Segmental Glomerulosclerosis	August 2012	Phase 2
NCT01472731	University Medical Center Groningen\|Genzyme, a Sanofi Company	Primary Brain Tumors	December 2011	Phase 2
NCT01112293	Abramson Cancer Center of the University of Pennsylvania	Pleural Malignant Mesothelioma	April 2010	Phase 2
NCT02581787	Maximilian Diehn\|Varian\|Stanford University	Stage IA Non-Small Cell Lung Carcinoma\|Stage IB Non-Small Cell Lung Carcinoma	August 2016	Phase 1\|Phase 2
NCT00125385	Genzyme, a Sanofi Company\|Sanofi	Idiopathic Pulmonary Fibrosis	July 2005	Phase 1

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Morris JC, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One. 2014;9(3):e90353. Published 2014 Mar 11.

Synonyms

Immunoglobulin G4, anti-(transforming growth factor β) (human monoclonal GC-1008 heavy chain), disulfide with human monoclonal GC-1008 light chain, dimer

Fresolimumab

GC 1008